Summary by Moomoo AI
Remegen Pharmaceuticals (Yantai) Co., Ltd. ("Remegen") announced its interim report for 2024, showing a revenue of RMB 739,656 thousand for the period, an increase compared to the same period last year. However, the company recorded a loss of RMB 780,460 thousand during the same period, with a gross profit of RMB 570,385 thousand. During the reporting period, Remegen continued to focus on research in the field of biomedical pharmaceuticals, biomedical services, and the production and sale of biomedical products. The company has business income in both mainland China and the USA market, with mainland China being the main market. As of June 30, 2024, Remegen's non-current assets were valued at RMB 3,260,658 thousand, and current assets were valued at RMB 2,493,879 thousand. Cash and cash equivalents at the end of the period amounted to RMB 673,322 thousand. The company did not declare or pay any interim dividends.
